Bio

Tom has nearly 20 years of venture capital experience and securities analyst experience. He represents or has represented Nexus on the Boards of Presidio Pharmaceuticals, SpectraAnalysis, EyeGate Pharmaceuticals, MyoScience and Magellan Biosciences. Over the last several years, Tom has led investments in numerous successful private companies, including Panacos Pharmaceuticals and Atricure. Prior to joining Nexus, Tom was a Managing Director and Senior Equity Analyst at U. S. Bancorp Piper Jaffray covering publicly traded biopharmaceutical companies and drug discovery supplier companies. While at Piper, he published research notes, reports, industry overviews and technology updates for the benefit of the investment community on Gilead Sciences, Tularik, Human Genome Sciences, Millennium Pharmaceuticals, Applied Biosystems, Charles River Laboratories, Invitrogen and Millipore, among others. Tom also participated in the identification, analysis and recommendation of many companies both pre- and post-IPO. Previously, he was Senior Analyst at Leerink Swann & Company, published equity research on public biopharmaceutical companies including Genentech, Biogen, Amgen and Vertex Pharmaceuticals, among others. Tom was a Senior Research Associate at NationsBanc Montgomery Securities as well as worked in the business development group at Genentech. He was a research scientist at Cor Therapeutics and Genentech. Tom holds a B.S. degree in molecular biology and an MBA, both from the University of California, Berkeley.